BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27323245)

  • 1. Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.
    Vreeland TJ; Clifton GT; Herbert GS; Hale DF; Jackson DO; Berry JS; Peoples GE
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1347-1357. PubMed ID: 27323245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
    Chick RC; Faries MB; Hale DF; Kemp Bohan PM; Hickerson AT; Vreeland TJ; Myers JW; Cindass JL; Brown TA; Hyngstrom J; Berger AC; Jakub JW; Sussman JJ; Shaheen M; Clifton GT; Park H; Sloan AJ; Wagner T; Peoples GE
    Cancer Med; 2021 Jul; 10(13):4302-4311. PubMed ID: 33982452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.
    Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A
    Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
    Bose A; Lowe DB; Rao A; Storkus WJ
    Melanoma Res; 2012 Jun; 22(3):236-43. PubMed ID: 22504156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
    Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
    Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
    Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
    Front Immunol; 2021; 12():623639. PubMed ID: 33692796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
    Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
    J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice.
    Jarosz-Biej M; Smolarczyk R; Cichoń T; Kułach N; Czapla J; Matuszczak S; Szala S
    Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):451-64. PubMed ID: 25801067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
    Geskin LJ; Damiano JJ; Patrone CC; Butterfield LH; Kirkwood JM; Falo LD
    Melanoma Res; 2018 Jun; 28(3):211-221. PubMed ID: 29543704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.
    Thomann S; Boscheinen JB; Vogel K; Knipe DM; DeLuca N; Gross S; Schuler-Thurner B; Schuster P; Schmidt B
    Immunology; 2015 Oct; 146(2):327-38. PubMed ID: 26194553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.
    Berry J; Vreeland T; Trappey A; Hale D; Peace K; Tyler J; Walker A; Brown R; Herbert G; Yi F; Jackson D; Clifton G; Peoples GE
    Expert Rev Clin Immunol; 2017 Mar; 13(3):235-245. PubMed ID: 27552944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
    González FE; Chernobrovkin A; Pereda C; García-Salum T; Tittarelli A; López MN; Salazar-Onfray F; Zubarev RA
    J Immunol Res; 2018; 2018():3982942. PubMed ID: 29744371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
    Martins F; Orcurto A; Michielin O; Coukos G
    Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
    McKenzie JA; Mbofung RM; Malu S; Zhang M; Ashkin E; Devi S; Williams L; Tieu T; Peng W; Pradeep S; Xu C; Zorro Manrique S; Liu C; Huang L; Chen Y; Forget MA; Haymaker C; Bernatchez C; Satani N; Muller F; Roszik J; Kalra A; Heffernan T; Sood A; Hu J; Amaria R; Davis RE; Hwu P
    J Natl Cancer Inst; 2018 Jul; 110(7):777-786. PubMed ID: 29267866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
    Lee N; Zakka LR; Mihm MC; Schatton T
    Pathology; 2016 Feb; 48(2):177-87. PubMed ID: 27020390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations.
    Tuettenberg A; Schmitt E; Knop J; Jonuleit H
    J Dtsch Dermatol Ges; 2007 Mar; 5(3):190-6. PubMed ID: 17338793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
    Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
    J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.